New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19.
Southeast Asia is the source of 95 percent of global cassava exports, and the detection in 2015 in Cambodia of the potentially harvest-devastating Sri Lankan cassava mosaic virus (SLCMV) raised alarm. By 2016, the disease, which cannot always be detected visually, had spread, showing its potential to become a major threat to the livelihoods of millions of smallholder farming families.
The sixth meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (2005) (IHR) regarding the coronavirus disease (COVID-19) took place on Thursday, 14 January 2021 from 12:15 to 16:45 Geneva time (CEST).
As we enter the second year of living with the new coronavirus SARS-CoV-2, the virus is celebrating its invasion of the world’s population with yet more mutated forms that help it to spread more easily from person to person.
This is an update of an article originally published on November 24, 2020. New data is coming in on the efficacy of the various vaccines, and the Pfizer-BioNTech and Moderna vaccines are being distributed in the U.S. and other countries.
The death rate for Nipah virus is up to 75% and it has no vaccine. While the world focuses on Covid-19, scientists are working hard to ensure it doesn’’t cause the next pandemic.
Health workers distributing the COVID-19 vaccine have been forced to take extra precautions after Spain was paralyzed by Storm Filomena. The snowfall in Madrid reached a level unseen in half a century.
A pharmacist dilutes the Pfizer COVID-19 vaccine while preparing it to administer to staff and residents at the Goodwin House Bailey’s Crossroads, a senior living community in Falls Church, Virginia, on December 30, 2020.
Worldwide, the number of potential pathogens is very large, while the resources for disease research and development (R&D) is limited. To ensure efforts under WHO’s R&D Blueprint are focused and productive, a list of diseases and pathogens are prioritized for R&D in public health emergency contexts.